Wealthfront Advisers LLC Increases Holdings in Zoetis Inc. $ZTS

Wealthfront Advisers LLC increased its stake in shares of Zoetis Inc. (NYSE:ZTS) by 80.2% during the second quarter, HoldingsChannel.com reports. The institutional investor owned 76,113 shares of the company’s stock after acquiring an additional 33,873 shares during the quarter. Wealthfront Advisers LLC’s holdings in Zoetis were worth $5,469,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the stock. University of Texas Texas AM Investment Management Co. acquired a new stake in shares of Zoetis in the 2nd quarter worth $25,000. Dunhill Financial LLC boosted its position in shares of Zoetis by 519.3% during the 2nd quarter. Dunhill Financial LLC now owns 353 shares of the company’s stock valued at $25,000 after acquiring an additional 296 shares during the last quarter. Prosperity Bancshares Inc purchased a new position in Zoetis during the fourth quarter worth about $25,000. Cassaday & Co Wealth Management LLC acquired a new stake in shares of Zoetis during the 1st quarter worth approximately $28,000. Finally, Root Financial Partners LLC raised its position in shares of Zoetis by 66.5% during the 1st quarter. Root Financial Partners LLC now owns 258 shares of the company’s stock valued at $30,000 after buying an additional 103 shares during the period. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

ZTS has been the topic of a number of research analyst reports. Wall Street Zen downgraded Zoetis from a “buy” rating to a “hold” rating in a research report on Saturday, May 2nd. Piper Sandler lowered their target price on shares of Zoetis from $90.00 to $80.00 and set a “neutral” rating for the company in a research note on Monday, August 10th. Zacks Research cut shares of Zoetis from a “hold” rating to a “strong sell” rating in a research report on Monday, August 10th. Barclays reduced their price target on shares of Zoetis from $136.00 to $85.00 and set an “equal weight” rating on the stock in a research note on Wednesday, July 1st. Finally, HSBC lowered their price objective on shares of Zoetis from $140.00 to $95.00 and set a “buy” rating for the company in a research report on Monday, July 6th. Eight equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $109.23.

Zoetis Trading Down 2.0%

NYSE:ZTS opened at $75.13 on Friday. The stock has a fifty day moving average price of $75.79 and a 200 day moving average price of $97.47. The company has a current ratio of 3.08, a quick ratio of 1.84 and a debt-to-equity ratio of 2.87. The firm has a market cap of $31.05 billion, a PE ratio of 12.38, a price-to-earnings-growth ratio of 1.79 and a beta of 0.74. Zoetis Inc. has a 12-month low of $71.00 and a 12-month high of $159.00.

Zoetis (NYSE:ZTS) last released its earnings results on Thursday, August 6th. The company reported $1.87 earnings per share for the quarter, topping analysts’ consensus estimates of $1.85 by $0.02. The firm had revenue of $2.47 billion for the quarter, compared to analyst estimates of $2.50 billion. Zoetis had a net margin of 27.49% and a return on equity of 74.89%. The business’s quarterly revenue was down .2% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.76 earnings per share. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. Sell-side analysts anticipate that Zoetis Inc. will post 6.2 earnings per share for the current fiscal year.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.